Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FEVOSURZE-FE is a small molecule hematinic formulation developed by Miotic Pharmaceuticals. It is an approved nutritional supplement designed for the treatment and prevention of iron-deficiency anemia and other megaloblastic anemias. The product typically functions as a combination of essential hematopoietic factors, including iron (often as ferrous fumarate), folic acid, and vitamin B12 (cyanocobalamin). Iron is a critical component of hemoglobin, necessary for oxygen transport, while folic acid and vitamin B12 serve as essential cofactors in DNA synthesis and the maturation of erythrocytes. This combination therapy is particularly indicated for individuals with increased nutritional requirements, such as pregnant women, or those with malabsorption or dietary deficiencies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FEVOSURZE-FE.